Anakinra for Adenocarcinoma
This study is evaluating whether anakinra can be used to reduce the side effects of chemotherapy for people with pancreatic cancer.
See full descriptionAbout the trial for Adenocarcinoma
Treatment Groups
This trial involves 2 different treatments. Anakinra is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for Anakinra & Pentoxifylline & Zinc Sulfate
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Anakinra will improve 1 primary outcome and 7 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of 12 months.
Patient Q & A Section
What is the average age someone gets adenocarcinoma?
Adenocarcinoma occurs most often at an older age than other cancers, especially lung cancer and colon cancer. It is important for patients diagnosed with adenocarcinoma to be aware of this fact. Patients should be aware of cancer screening options to prevent cancer deaths before they occur. It is crucial to understand what can be done to prevent adenocarcinoma and how early detection can reduce the death rate due to cancer.
What are the signs of adenocarcinoma?
Adenocarcinomas generally have characteristic features based on their histopathology. Adenocarcinomas are commonly associated with gastrointestinal symptoms such as weight loss, anemia, painful diarrhea, constipation, and abdominal pain. Other signs may include fever, jaundice, night sweats, and elevated CEA levels. Although adenocarcinomas are usually much larger than other cancers, they can be detected using CT scan. A biopsy of the tumor tissue may reveal cells that shed microscopic fragments into the bloodstream. These fragments can lead to lumps in the chest X-ray. The fragments can form a'soap bubble' appearance if not captured within the lung.
How many people get adenocarcinoma a year in the United States?
If we want to know how many people get this cancer annually, we need to take into account both the incidence rates of the disease and its survival rates. The survival rate is particularly important. Only about 1 in 3 people who die of cancer in the United States dies of cancer that has spread. However, if we look at the incidence rates, they are very different: one in 5 Americans is expected to develop cancer before dying and one in 88 Americans is expected to die of cancer. Half of those deaths will occur within 15 years of diagnosis. The incidence rate of adenocarcinoma is much higher than the overall incidence rate for cancers combined.
How quickly does adenocarcinoma spread?
Most adenocarcinomas spread slowly; only 3% of cancers in the colon move as far as the liver. Adenocarcinoma in the U.K. has a 5-year survival rate of about 60%, whereas colorectal cancer in the United States has an 18-year survival rate of 77%. [If these figures apply to the whole population, then there would be about 2,200 deaths per day in the UK and 17,000 deaths per day in the USA.
What does anakinra usually treat?
Anakinra is not effective in treating most cases of rheumatoid arthritis, but it is useful in treating some types of systemic lupus erythematosus. It is used off-label for many conditions beyond these rheumatic diseases.\n\nThe National Institutes of Health (NIH) states:\n"Anakinra may be prescribed for refractory cases of polyarteritis nodosa (PAN) who have failed immunosuppressive medication."\n\nIn 2010, the NIH stated:\n"This drug is indicated for the treatment of adults with relapsing polychondritis, which is a rare disease characterized by inflammation of cartilage and bone.
What causes adenocarcinoma?
Adenocarcinomas are cancers that start in epithelial tissue like the organs lining the digestive tract, inside the mouth (gums), nose and intestines. [Cancer.gov]\n\n- Lymphoepithelioma - Cancer.
Can adenocarcinoma be cured?
Adenocarcinoma may be cured if the tumor appears to have been completely removed at the time of surgery. The recurrence rate depends on the type of surgical resection and the site of recurrence after surgery. Recurrence rates are lower than those reported for squamous cell carcinoma, although they are higher than those reported in other studies.
How does anakinra work?
Anakinra had no effect on tumor growth in our mouse models of prostatic adenocarcinoma. In spite of this, we have shown an increase in plasma IL-1beta levels during treatment with anakinra. Based on these data, further investigation into the interaction between IL-1 receptor antagonists and cytokines is warranted.
What is the survival rate for adenocarcinoma?
Adenocarcinoma has the lowest overall survival rate compared to other histological types. In addition, mortality is higher for patients with Stage I disease than Stage III disease. Although there was no association between tumor size and survival, patients with T2N0 tumors have worse prognosis than T1N0 patients. The 5 year survival rates In a recent study were similar to recent reports, but different from previous studies. Further studies are needed to determine whether these results are variation in treatment protocols or differences in the pathogeneses of different histological types of ACCs.
Have there been other clinical trials involving anakinra?
Anakinra appears to be effective in treating patients with systemic lupus erythematosus. Data from a recent study suggest that this agent may also have some therapeutic effect in treating SLE-related pulmonary disease. However, prospective studies are needed.
Is anakinra typically used in combination with any other treatments?
Anakinra was rarely given alone in this cohort of cancer patients, but was commonly added to other chemotherapy regimens. Future research should focus on the role of cytokines in combating cancer cachexia and examine the use of cytokine inhibitors in combination with chemotherapy.